Entities / Company
AngioDynamics (United States).
company in California City, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
Gone quiet
No new reports in 90+ days-
AngioDynamics received FDA 510(k) clearance and began international clinical trials in Europe and Hong Kong.Speculative1 report
-
AngioDynamics is classified in the Medical Instruments Industry and has been underperforming the market so far this year.Some support1 report
-
AngioDynamics' Auryon Atherectomy System is currently being tested in clinical trials.Some support2 reports
-
The medical equipment industry in the US is projected to grow at 8.2% per annum, based on a forecast from July 17, 2025.Some support2 reports
-
Prostate cancer is reported as a common condition among men in the United States.Some support1 report
-
AngioDynamics presented at a conference on August 7, 2025, with Jim Clemmer as CEO and Stephen Trowbridge as CFO.Some support1 report
-
AngioDynamics received FDA clearance for its NanoKnife product, which was reported alongside its stock performance relative to the S&P 500.Some support2 reports
-
James Clemmer made the biggest insider purchase at AngioDynamics on August 27, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around AngioDynamics (United States) this week
News at the entities that move AngioDynamics (United States) most-
Incepta Pharmaceuticals Mentioned togetherTilray Brands, Inc.'s stock change lagged the S&P 500 gain on August 28, 2025, while the company holds a Zacks Rank of #3.Moves AngioDynamics (United States)
Connections
The 1 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Incepta Pharmaceuticals Mentioned together
Both companies are members of the Medical - Instruments industry sector.
History
Events by the month they beganJune 2026
8 events- AngioDynamics received FDA 510(k) clearance and began international clinical trials in Europe and Hong Kong.
- AngioDynamics is classified in the Medical Instruments Industry and has been underperforming the market so far this year.
- AngioDynamics' Auryon Atherectomy System is currently being tested in clinical trials.
- The medical equipment industry in the US is projected to grow at 8.2% per annum, based on a forecast from July 17, 2025.
- Prostate cancer is reported as a common condition among men in the United States.
- AngioDynamics presented at a conference on August 7, 2025, with Jim Clemmer as CEO and Stephen Trowbridge as CFO.
- AngioDynamics received FDA clearance for its NanoKnife product, which was reported alongside its stock performance relative to the S&P 500.
- James Clemmer made the biggest insider purchase at AngioDynamics on August 27, 2025.